HEAD-DROP: A FREQUENT FEATURE OF LATE-ONSET MYASTHENIA GRAVIS

被引:17
|
作者
Sih, Marvin [1 ]
Soliven, Betty [1 ]
Mathenia, Nicholas [1 ]
Jacobsen, John [1 ]
Rezania, Kourosh [1 ]
机构
[1] Univ Chicago, Med Ctr, Dept Neurol, 5841 S Maryland Ave,MC 2030, Chicago, IL 60637 USA
关键词
acetylcholine receptor antibody; dropped head; head-drop; late-onset; MuSK; myasthenia gravis; respiratory weakness; PROTEIN; 4; AUTOANTIBODIES; MUSK; SIGN; MYOPATHY; DISEASE;
D O I
10.1002/mus.25526
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Head-drop is often encountered in myasthenia gravis (MG) patients, but its frequency and clinical course have not been studied systematically. Methods: In a retrospective study of a cohort of MG patients seen over a period of 11 years in a tertiary medical center, we assessed the clinical characteristics of patients who had head-drop. Results: Of 146 generalized MG patients, 15 had head-drop during the course of their disease. Head-drop patients had older age of onset than those who did not have head-drop (mean age of onset 59.1 vs. 42.3 years) and were predominantly men. Head-drop was present in 23% of patients > 60 versus 6% of those < 60 years, and it improved in 9 of 11 patients with treatment directed to generalized MG. Conclusions: Head-drop is a common, treatment-responsive manifestation of late-onset MG.
引用
收藏
页码:441 / 444
页数:4
相关论文
共 50 条
  • [41] Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients
    Yu, Lu
    Qiu, Li
    Ran, Hao
    Ma, Qian
    Lu, Ya-Ru
    Liu, Wei-Bin
    WORLD JOURNAL OF PSYCHIATRY, 2022, 12 (03): : 470 - 482
  • [42] COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature
    Virgilio, Eleonora
    Tondo, Giacomo
    Montabone, Claudia
    Comi, Cristoforo
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2023, 20 (01)
  • [43] Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta-Analysis
    Chen, Jiaxin
    Su, Chunhua
    Feng, Huiyu
    Kaminski, Henry J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2025, 32 (03)
  • [44] Outcome measures and treatment effectiveness in late onset myasthenia gravis
    Francesca Pasqualin
    Silvia V. Guidoni
    Mario Ermani
    Elena Pegoraro
    Domenico M. Bonifati
    Neurological Research and Practice, 2
  • [45] Outcome measures and treatment effectiveness in late onset myasthenia gravis
    Pasqualin, Francesca
    Guidoni, Silvia V.
    Ermani, Mario
    Pegoraro, Elena
    Bonifati, Domenico M.
    NEUROLOGICAL RESEARCH AND PRACTICE, 2020, 2 (01):
  • [46] A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis
    M. I. Stefanou
    L. Komorowski
    S. Kade
    A. Bornemann
    U. Ziemann
    M. Synofzik
    BMC Neurology, 16
  • [47] Late onset immunodeficiency in a patient with recurrent thymic carcinoma and myasthenia gravis
    Schmidt, S
    Padberg, F
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 157 (02) : 201 - 205
  • [48] Fatigue: an important feature of late-onset Pompe disease
    Hagemans, Marloes L. C.
    van Schie, Sabine P. M.
    Janssens, A. Cecile J. W.
    Van Doorn, Pieter A.
    Reuser, Arnold J. J.
    van der Ploeg, Ans T.
    JOURNAL OF NEUROLOGY, 2007, 254 (07) : 941 - 945
  • [49] Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin's lymphoma
    Dang, Thai
    Macwan, Samir
    Dasanu, Constantin A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (06) : 1534 - 1538
  • [50] Fatigue: an important feature of late-onset Pompe disease
    M. L. C. Hagemans
    S. P. M. van Schie
    A. C. J. W. Janssens
    P. A. van Doorn
    A. J. J. Reuser
    A. T. van der Ploeg
    Journal of Neurology, 2007, 254 : 941 - 945